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Introduction 
 Aging is a process that’s inevitable. Over a typical 
lifespan, the body loses its ability to maintain homeostasis 
and fight off disease. The elderly also experience athero-
sclerosis that can lead to strokes and myocardial infarc-
tions. Arthritic joint pain and stiffness are also common, as 
is thinning of the skin. Researches have speculated about 
the precise physical changes in the body that manifest 
themselves as the process of aging (Burtner and Kennedy 
2010). 
The answer may lie in a very rare segment of the popula-
tion who suffer from progeriod syndromes that cause ac-
celerated aging. The most severe of this group is Progeria, 
which causes rapid aging in children and death by adoles-
cence. The calculated mean lifespan in Progeria patients is 
only 13 years of age (Kudlow et al. 2007). 
HGPS Pathophysiology 
 Hutchinson-Gilford Progeria Syndrome (HGPS) is 
caused by a de novo heterozygous point mutation, chang-
ing a GGC sequence to GGT in exon 11 of the LMNA gene. 
This mutation causes a 50 amino acid sequence deletion at 
the carboxyl terminus of prelamin A, producing a truncat-
ed progerin in the place of Lamin A (Neelam et al. 2012). 
Lamins are intermediate filament proteins that polymerize 
to form nuclear lamina, a meshwork forming the inner nu-
clear membrane. Lamin A belongs to the A-type lamins 
that includes Lamin A and Lamin C. Lamin C differs very 
slightly from Lamin A by its C-terminal extension, which 
has 90 less residues than Lamin A. Both Lamin A and C con-
tribute to the shaping of the nuclear membrane. When 
progerin is present in place of Lamin A, the nuclear mem-
brane takes on an abnormal morphology (Rakha, et al. 
2011). 
The Proteins of the nuclear lamina were once thought to 
play merely a structural role. Through studying diseases 
that affect these proteins, it has become apparent that 
they also play an important role in various cellular func-
tions such as signal transduction and gene expression 
(Scaffidi and Misteli, 2006). Therefore, mutations affecting 
these proteins can have devastating effects on multiple 
organ systems in the body, as in the case of Hutchinson-
Gilford Progeria Syndrome (HGPS). 
 HGPS is part of a group of rare diseases known as 
laminopathies, in which the proteins of the nuclear lamina 
are affected. These diseases all result from LMNA gene 
mutations and include lipodystrophy, muscular dystrophy, 
peripheral neuropathy and Progeria (Liu, et al. 2010). In 
lipodystrophy, symptoms begin at the onset of puberty 
and patients experience loss of subcutaneous fat, high cho-
lesterol and type-II diabetes.  Muscular dystrophy is similar 
in that symptoms appear close to puberty and cause pro-
gressive muscle wasting. Peripheral Neuropathy is a lami-
nopathy that causes nerve dysfunction. Progeria is perhaps 
the most devastating of them all since symptom onset be-
gins at a few months of age and death from cardiovascular 
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illness is likely by age 13. 
HGPS Phenotypes 
HGPS disease symptoms include; slow growth, scleroder-
matous changes of the skin, alopecia, osteoporosis and 
atherosclerotic vascular disease.  (Yang, et al. 2006) These 
symptoms contribute to a very distinctive look common to 
all Progeria patients. They are sometimes described as ap-
pearing like ‘little aliens’ due to their diminutive stature, 




 In one particular Chinese girl with Progeria, HGPS 
diagnosis was made at 2 months of age. The child was the 
second-born of healthy parents with no remarkable family 
medical history. The first symptom that raised concern was 
a loss of subcutaneous fat in her abdomen and buttocks, 
where a baby would normally exhibit plumpness. Her hair 
was also unusually sparse and her veins were noticeably 
prominent for 2 months of age (Chen, et al. 2012). 
 At 2 years of age, the child had already lost all of 
her hair and was beginning to develop a characteristic Pro-
geria face. Her forehead jutted out, her eyes were promi-
nent and her jaw was undersized. Imaging studies taken 
over ages 4 and 5, showed patterns of bone resorption in 
her clavicles and distal phalanges along with hip displace-
ment and dental crowding (Ibid).   
 The symptoms progressed rapidly and by age 6 the 
deformities caused speech and swallowing difficulties and 
hearing loss. When measured at age 8, she fell below the 
3rd percentile in both height and weight compared to oth-
er her age and she remained very thin and small in stature 
(Ibid).   
 Diagnoses came later for an Indian boy who 
showed up at a Dermatology clinic at age 4. He had loss of 
hair, including eyelashes and eyebrows since age 1, and 
stunted growth. Doctors noticed his distinct prominent 
veins and eyes, beaked nose and high-pitched voice. His 
problems were far from merely dermatological, and he 
was diagnosed with Progeria after confirmatory imaging 
studies (Agarwal, et al. 2010) 
Vertebrate Progeriod Models 
 Researchers attempting to better understand and 
treat Progeria, need models to work with. The incidence of 
Progeria is so infrequent in the population due to the rarity 
of the specific LMNA mutation that causes it. Nearly all 
Progeria patients in the world today are well known and 
have participated in studies by contributing medical data 
and samples. In the century or so since the discovery of the 
syndrome, only about 100 cases have been documented 
(Mohamed and Jayachandran 2009) and today, with only 
48 known patients whose lifespans are short, these sam-
ples are severely limited. 
 Human Progeria research subjects are not only 
limited in number, it often isn’t safe for them to participate 
in early stages of drug trials. Before a drugs potency can be 
determined, use in humans is unethical. Thus, creating ani-
mal models to test Progeria drugs is an important key to 
ultimately finding a cure. 
 After much trial and error, mice have been suc-
cessfully genetically modified to be ZMPSTE24 deficient, 
causing the expression of Progeria-like symptoms (Osorio, 
et al. 2009). ZMPSTE24 is an enzyme that completes the 
post-translational processing of Pre-lamin A by cleaving it 
into its mature form of lamin A (Liu, et al. 2010). Without 
the ZMPSTE24 enzyme, Pre-lamin A processing is halted 
and this results in a truncated Lamin A protein similar to 
the progerin protein found in patients with HGPS. 
 Zebrafish models expressing truncated Lamin A 
Figure 1: Face of a Progeria patient showing alopecia, loss 
of eyebrow and eyelashes and prominent eyes with a ta-
pered nasal tip. (Agarwal, et al. 2010) 
Hutchinson-Gilford Progeria Syndrome: Pathophysiology and Possible Treatments 
Introduction 
 Aging is a process that’s inevitable. Over a typical 
lifespan, the body loses its ability to maintain homeostasis 
and fight off disease. The elderly also experience athero-
sclerosis that can lead to strokes and myocardial infarc-
tions. Arthritic joint pain and stiffness are also common, as 
is thinning of the skin. Researches have speculated about 
the precise physical changes in the body that manifest 
themselves as the process of aging (Burtner and Kennedy 
2010). 
The answer may lie in a very rare segment of the popula-
tion who suffer from progeriod syndromes that cause ac-
celerated aging. The most severe of this group is Progeria, 
which causes rapid aging in children and death by adoles-
cence. The calculated mean lifespan in Progeria patients is 
only 13 years of age (Kudlow et al. 2007). 
HGPS Pathophysiology 
 Hutchinson-Gilford Progeria Syndrome (HGPS) is 
caused by a de novo heterozygous point mutation, chang-
ing a GGC sequence to GGT in exon 11 of the LMNA gene. 
This mutation causes a 50 amino acid sequence deletion at 
the carboxyl terminus of prelamin A, producing a truncat-
ed progerin in the place of Lamin A (Neelam et al. 2012). 
Lamins are intermediate filament proteins that polymerize 
to form nuclear lamina, a meshwork forming the inner nu-
clear membrane. Lamin A belongs to the A-type lamins 
that includes Lamin A and Lamin C. Lamin C differs very 
slightly from Lamin A by its C-terminal extension, which 
has 90 less residues than Lamin A. Both Lamin A and C con-
tribute to the shaping of the nuclear membrane. When 
progerin is present in place of Lamin A, the nuclear mem-
brane takes on an abnormal morphology (Rakha, et al. 
2011). 
The Proteins of the nuclear lamina were once thought to 
play merely a structural role. Through studying diseases 
that affect these proteins, it has become apparent that 
they also play an important role in various cellular func-
tions such as signal transduction and gene expression 
(Scaffidi and Misteli, 2006). Therefore, mutations affecting 
these proteins can have devastating effects on multiple 
organ systems in the body, as in the case of Hutchinson-
Gilford Progeria Syndrome (HGPS). 
 HGPS is part of a group of rare diseases known as 
laminopathies, in which the proteins of the nuclear lamina 
are affected. These diseases all result from LMNA gene 
mutations and include lipodystrophy, muscular dystrophy, 
peripheral neuropathy and Progeria (Liu, et al. 2010). In 
lipodystrophy, symptoms begin at the onset of puberty 
and patients experience loss of subcutaneous fat, high cho-
lesterol and type-II diabetes.  Muscular dystrophy is similar 
in that symptoms appear close to puberty and cause pro-
gressive muscle wasting. Peripheral Neuropathy is a lami-
nopathy that causes nerve dysfunction. Progeria is perhaps 
the most devastating of them all since symptom onset be-
gins at a few months of age and death from cardiovascular 
Abstract 
Named after the two scientist who independently described the condition, Hutchinson-Gilford Progeria Syndrome 
(HGPS) occurs due to a mutation in the LMNA gene that codes for Lamin A, a filament protein that acts to form the nu-
clear lamina in the cell nucleus. This mutation is a single C-to-T substitution at nucleotide 1824 of the LMNA gene. As a 
result of this mutation, an abnormal protein named 'progerin' is synthesized instead of Lamin A, causing the nuclear 
membrane to be malformed. Since protein farnesylation is needed to target progerin to the nuclear rim, farnesyltrans-
ferase inhibitor has been proposed as a form of treatment that could reduce the occurrence of misshapen nuclei and 
alleviate HGPS symptoms. 
Hutchinson-Gilford Progeria Syndrome: 
Pathophysiology and Possible Treatments 
Pearl Hersh 
Perl Hersh graduated with a B.S. in Biology and will be attending New York Medical College . 
61 
 
illness is likely by age 13. 
HGPS Phenotypes 
HGPS disease symptoms include; slow growth, scleroder-
matous changes of the skin, alopecia, osteoporosis and 
atherosclerotic vascular disease.  (Yang, et al. 2006) These 
symptoms contribute to a very distinctive look common to 
all Progeria patients. They are sometimes described as ap-
pearing like ‘little aliens’ due to their diminutive stature, 




 In one particular Chinese girl with Progeria, HGPS 
diagnosis was made at 2 months of age. The child was the 
second-born of healthy parents with no remarkable family 
medical history. The first symptom that raised concern was 
a loss of subcutaneous fat in her abdomen and buttocks, 
where a baby would normally exhibit plumpness. Her hair 
was also unusually sparse and her veins were noticeably 
prominent for 2 months of age (Chen, et al. 2012). 
 At 2 years of age, the child had already lost all of 
her hair and was beginning to develop a characteristic Pro-
geria face. Her forehead jutted out, her eyes were promi-
nent and her jaw was undersized. Imaging studies taken 
over ages 4 and 5, showed patterns of bone resorption in 
her clavicles and distal phalanges along with hip displace-
ment and dental crowding (Ibid).   
 The symptoms progressed rapidly and by age 6 the 
deformities caused speech and swallowing difficulties and 
hearing loss. When measured at age 8, she fell below the 
3rd percentile in both height and weight compared to oth-
er her age and she remained very thin and small in stature 
(Ibid).   
 Diagnoses came later for an Indian boy who 
showed up at a Dermatology clinic at age 4. He had loss of 
hair, including eyelashes and eyebrows since age 1, and 
stunted growth. Doctors noticed his distinct prominent 
veins and eyes, beaked nose and high-pitched voice. His 
problems were far from merely dermatological, and he 
was diagnosed with Progeria after confirmatory imaging 
studies (Agarwal, et al. 2010) 
Vertebrate Progeriod Models 
 Researchers attempting to better understand and 
treat Progeria, need models to work with. The incidence of 
Progeria is so infrequent in the population due to the rarity 
of the specific LMNA mutation that causes it. Nearly all 
Progeria patients in the world today are well known and 
have participated in studies by contributing medical data 
and samples. In the century or so since the discovery of the 
syndrome, only about 100 cases have been documented 
(Mohamed and Jayachandran 2009) and today, with only 
48 known patients whose lifespans are short, these sam-
ples are severely limited. 
 Human Progeria research subjects are not only 
limited in number, it often isn’t safe for them to participate 
in early stages of drug trials. Before a drugs potency can be 
determined, use in humans is unethical. Thus, creating ani-
mal models to test Progeria drugs is an important key to 
ultimately finding a cure. 
 After much trial and error, mice have been suc-
cessfully genetically modified to be ZMPSTE24 deficient, 
causing the expression of Progeria-like symptoms (Osorio, 
et al. 2009). ZMPSTE24 is an enzyme that completes the 
post-translational processing of Pre-lamin A by cleaving it 
into its mature form of lamin A (Liu, et al. 2010). Without 
the ZMPSTE24 enzyme, Pre-lamin A processing is halted 
and this results in a truncated Lamin A protein similar to 
the progerin protein found in patients with HGPS. 
 Zebrafish models expressing truncated Lamin A 
Figure 1: Face of a Progeria patient showing alopecia, loss 
of eyebrow and eyelashes and prominent eyes with a ta-
pered nasal tip. (Agarwal, et al. 2010) 
Hutchinson-Gilford Progeria Syndrome: Pathophysiology and Possible Treatments 
62 
 
proteins have also been genetically engineered and stud-
ied. Using a splice-block method to delete the 8 amino-acid 
site of pre-lamin A cleavage in zebrafish embryos, re-
searchers created progeriod zebrafish models. These 
zebrafish then exhibited accelerated aging and shortened 
lifespans along with other symptoms such as cell-cycle ar-
rest and cartilage defects that appeared as craniofacial 
abnormalities (Koshimizu, et al. 2011). 
 Both the ZMPSTE24 deficient mice and the 
progeriod zebrafish models were genetically altered in a 
way where Lamin A was not able to be processed into its 
mature form. Another mouse model however, was modi-
fied so that it would not produce the Lamin A protein at all. 
This lamin A deficient mouse would only produce Lamin C, 
a similar Lamin protein normally produced alongside Lamin 
A. The Lamin C-only mice had no tissue abnormalities and 
appeared non-diseased (Fong et. al 2006). 
 In a state of complete lack of Lamin A, Lamin C 
seems to compensate and therefore, no pathologies result. 
It seems that the truncated, pre-lamin or progerin form of 
the Lamin A that accumulates when the protein’s pro-
cessing is halted, is the cause of the diseased cell (Fong et. 
al 2006). This realization can help researchers treat lamino-
pathic diseases by developing drugs that can prevent im-
mature lamin proteins from doing harm and possibly trig-
ger the non-affected Lamin types (unaffected Lamin C in 
Progeria patients) to compensate for the missing protein. 
FTI Treatment  
 The advantage of farnesyltransferase inhibitor (FTI) 
is that it can mask HGPS symptoms even while the abnor-
mal Progerin protein is still being expressed. By preventing 
progerin from attaching to the nuclear rim, FTI can in-
crease the amount of normal-shaped nuclei (Capell, et al. 
2005). 
 Prelamin A requires a 3-step prenylation pro-
cessing to be converted into mature Lamin A. The prenyla-
tion occurs rapidly and unprocessed Prelamin A is barely 
detectable (Gao, et al. 2009).  A similar form of post-
translational modification occurs in all CaaX proteins. This 
category of proteins contains a specific amino acid se-
quence at the c-terminal consisting of a cysteine residue, 2 
alipathic residues and another c-terminal acid ‘x’ that var-
ies, hence the acronym ‘CaaX Protein’. In Prelamin A, the 
CaaX terminal is made of cysteine, alipathic serine and iso-
leucine, and methionine (CSIM) (Dominici, et al. 2009). 
 In the first processing step of polyisoprenylation, 
farynesyltransferase recognizes methionine and adds a 15 
carbon farnesyl to the CSIM sequence. Proteolysis is next, 
in which endoprotease ZMPSTE24 removes the ‘SIM’ por-
tion of the CSIM sequence (Dominici, et al. 2009). In the 
final prenylation step, carboxyl methylation of the farnesyl-
ated prelamin A occurs via methyltransferase to produce 
carboxymethylated-farnesylated prelamin A (preLA-
farnesyl-C-H3). 
 
 Progerin, a truncated form of pre-lamin A, is miss-
ing the ZMPSTE24 cleavage site and will therefore retain 
the cysteine C-terminal that is farnesylated and carbox-
ymethylated (Liu, et al. 2010). The retention of the toxic 
farnesyl group will cause progerin to incorporate itself into 
the nuclear envelope in an abnormal fashion. Once in the 
nuclear envelope, progerin will produce an abnormal het-
erochromatin assembly and lead to an increase in DNA 
Pearl Hersh 
Figure 2: Prenylation process of the CAAX proteins. The pro-
tein prenylation process includes 3 steps: polyisoprenylation, 
proteolysis, and carboxyl methylation. Polyisoprenylation is the 
attachment of an isoprenoid lipid by protein farnesyltransfer-
ase (FTase) or geranylgeranytransferase type I (GGTase-I) to 
CAAX box. In the second step, the CAAX residues are prote-
olysed by prenyl protein peptidase RCE1 family to release - 
AAX. This is followed by subsequent endoproteolytic trimming 
and carboxyl methylation significantly increases the hydropho-
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damage (Zaremba-Czogalla et al. 2011).  Structurally, the 
nuclear membrane will also become misshapen and stiff. 
This characteristic is known as nuclear blebbing and is a 
distinct phenotype of progeria. 
 Lonafarnib, a farnesyltransferase inhibitor drug 
initially used for cancer treatment, has recently been test-
ed on patients with HGPS in a clinical trial. In 2007, 25 pro-
geria patients from 16 countries around the world came to 
Boston, Massachusetts over a period of 2 years to receive 
Lonafarnib. They were measured for changes in weight, 
skeletal rigidity, hearing and cardiovascular health.  The 
study showed that the children improved in at least one or 
more of the measured areas over the course of the trial. 
Most importantly, in the essential area of cardiovascular 
health, which is the cause of death in progeria patients, all 
but one participant showed improvement (Gordon, et al. 
2012) 
Other Treatments 
    In the presence of farnesyltranferase inhibitors, 
the cell will often adapt and turn to other processing path-
ways such as grenygrenylation (Gordon et al. 2008). In 
place of polyisoprenylation (addition of a 15-carbon farne-
syl) via farnesyltransferase, a similar enzyme, geranyl-
geranyltransferase I (GGTase I) can add a 20-carbon 
geranylgeranyl group to the Pre-lamin A (Sousa et al. 
2008). This adaptation mechanism can lessen the effective-
ness of FTI treatment. A combination of statins and amino-
bisphosphonates, combined with FTI treatment can inhibit 
both farnesylation and grenygrenylation pathways. 
 Although not originally developed for progeria, the 
statin Pravastatin and the aminobisphosphonate Zoledron-
ic acid have been implemented in a 2012 clinical trial, 
along with FTI Lanofarnib, in progeria pa-
tients.  Pravastatin, an HMG-CoA inhibitor, is often pre-
scribed to lower cholesterol levels and keep atherosclero-
sis from worsening. Zoledronic acid is used in bone cancers 
and multiple myeloma, can help prevent hyepercalcaemia 
that occurs in Progeria patients. These two drugs work 
principally by preventing farnesyl group formation, a pro-
cess vital to progerin in the course of the disease (Neelam 
et al. 2012). 
  Lastly, stem Cell use has been researched as a 
form of treatment. Since Lamin A expression is develop-
mentally regulated, it isn’t present in embryonic cells and 
stem cells (Mounkes et al. 2003). This can be seen in the 
normal appearance of Progeria-modeling mouse embryos 
and progeria patients up until a few months of age, when 
progerin starts to proliferate in cells in place of Lamin A. 
Stem cell use has been explored as a means of initiating 
tissue regeneration and offsetting the accelerated rate of 
cell aptosis that causes rapid aging in Progeria patients 
(Halaschek-Wiener and Brooks-Wilson 2007). 
Conclusion 
   Progeria is a rare, devastating and terminal disease 
caused by a single gene mutation. Since the mutation is 
located on the LMNA gene, the Nuclear Lamina Proteins 
are affected. A single nucleotide substitution causes a 50 
base pair deletion of pre-lamin A (Lain A pre-cursor). Lamin 
A is then prevented from completing its processing and 
remains in an immature form called progerin. The accumu-
lation of progerin has a multi-systemic effect leading to 
rapid aging and early death from complications of athero-
sclerosis. Lonafarnib, a FTI inhibitor, has been proposed as 
a form of treatment and recent studies have shown it is 
effective in alleviating some of the symptoms of Progeria. 
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 Although not originally developed for progeria, the 
statin Pravastatin and the aminobisphosphonate Zoledron-
ic acid have been implemented in a 2012 clinical trial, 
along with FTI Lanofarnib, in progeria pa-
tients.  Pravastatin, an HMG-CoA inhibitor, is often pre-
scribed to lower cholesterol levels and keep atherosclero-
sis from worsening. Zoledronic acid is used in bone cancers 
and multiple myeloma, can help prevent hyepercalcaemia 
that occurs in Progeria patients. These two drugs work 
principally by preventing farnesyl group formation, a pro-
cess vital to progerin in the course of the disease (Neelam 
et al. 2012). 
  Lastly, stem Cell use has been researched as a 
form of treatment. Since Lamin A expression is develop-
mentally regulated, it isn’t present in embryonic cells and 
stem cells (Mounkes et al. 2003). This can be seen in the 
normal appearance of Progeria-modeling mouse embryos 
and progeria patients up until a few months of age, when 
progerin starts to proliferate in cells in place of Lamin A. 
Stem cell use has been explored as a means of initiating 
tissue regeneration and offsetting the accelerated rate of 
cell aptosis that causes rapid aging in Progeria patients 
(Halaschek-Wiener and Brooks-Wilson 2007). 
Conclusion 
   Progeria is a rare, devastating and terminal disease 
caused by a single gene mutation. Since the mutation is 
located on the LMNA gene, the Nuclear Lamina Proteins 
are affected. A single nucleotide substitution causes a 50 
base pair deletion of pre-lamin A (Lain A pre-cursor). Lamin 
A is then prevented from completing its processing and 
remains in an immature form called progerin. The accumu-
lation of progerin has a multi-systemic effect leading to 
rapid aging and early death from complications of athero-
sclerosis. Lonafarnib, a FTI inhibitor, has been proposed as 
a form of treatment and recent studies have shown it is 
effective in alleviating some of the symptoms of Progeria. 
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Anesthetic Pathway / Mechanism 
 For conformation to occur between an anesthetic 
agent and its target, it would be expected that the agent 
would be highly specific. But the broad arrays of such 
agents, with their varied structural and chemical composi-
tions seem to belie such a nature. Nevertheless, all general 
anesthetics work through either of two primary transmis-
sion mechanisms: NMDA (N-methyl-D-aspartate) receptor 
antagonists or GABA mimetic receptors (gamma-
aminobutyric acid). 
 GABA receptors, a type of ligand-gated ion chan-
nel, are the main inhibitory neurotransmitter in the central 
nervous system (Colquhoun et al. 2004).  The sedative 
effect of the GABAa agonists is caused by the inhibition of 
firing new action potentials. When molecules bind extra-
cellularly, a selective Cl ion pore is opened. This increased 
accessibility of the Cl ion drives it towards -65mV, a mem-
brane potential at which there is no overall change in the 
ion concentration on either side of the membrane, a situa-
tion called reversal potential. 
 NMDA receptor antagonists block the glutamate 
and glycine from binding to the receptor, blocking signal 
transmission between the spinal cord and the brain (Olney 
et al. 1991). NMDA receptors are important in the function 
of neuronal migration and differentiation, synaptic plastici-
ty, and in promoting learning and memory. Glutamate re-
ceptors are the most common excitatory neurotransmitter 
found in mammals. NMDA glutamate receptor antagonists 
include ketamine and nitrous oxide, both widely used in 
pediatric anesthesia. The collective effect of GABAa ago-
nists and NMDA antagonists is to block synaptic transmis-
sions from occurring between neurons and the spinal cord. 
Methods 
 Data presented in this paper was mined from case 
studies, review articles, online sources, and scientific jour-
nals using search engines of the Touro College Library da-
tabase, EBSCO, Pubmed, and Google Scholar. 
Discussion 
Effects on lower mammals 
Deleterious effects of anesthetics on developing neural 
cells was first observed in extensive exposure of rat pups 
on postnatal days 0,3,7, and 21 to Dizocilpine [(+)MK 801], 
an NMDA receptor antagonist (Ikonomidou et al. 1999). 
NMDA receptor activation promotes survival of their re-
Abstract 
Recent studies suggest that general anesthetic (GA) agents administered to developing rats, through its mechanism as 
an NMDA antagonist or a GABAa mimetic, may damage developing neural cells by inducing a higher rate of programmed 
cell death (apoptosis). Similar heightened degeneration was also apparent in higher primates such as the monkey. This 
warrants strong concern, as every year thousands of pregnant women and children below 1 year of age undergo a surgi-
cal procedure in which GAs are used. A spike in neuroapoptosis may lead to long term cognitive deficiencies lingering 
into adulthood. Are humans vulnerable to these affects? Different pathways are under investigation as to the cause of 
the damage in animals, but humans have different metabolic pathways than even higher primates, and the basic mecha-
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